Defunct Company
Total Trials
11
As Lead Sponsor
10
As Collaborator
1
Total Enrollment
1,524
NCT02890537
Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head
Phase: Phase 2
Role: Collaborator
Start: Oct 31, 2003
Completion: Jan 31, 2015
NCT01529008
Study on Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head
Phase: Phase 3
Role: Lead Sponsor
Start: Nov 30, 2011
Completion: Nov 30, 2018
NCT01756326
Study on Autologous Osteoblastic Cells Implantation in Hypotrophic Non-Union Fractures
Phase: Phase 2/3
Start: Jun 30, 2012
Completion: Apr 30, 2019
NCT02020590
Phase 1/2a Study on Allogeneic Osteoblastic Cells Implantation in Delayed-Union Fractures
Phase: Phase 1/2
Start: Feb 28, 2014
Completion: Jan 30, 2020
NCT02328287
Study on Allogeneic Osteoblastic Cells Implantation in Rescue Interbody Fusion
Start: Sep 30, 2014
Completion: Apr 30, 2020
NCT02205138
Phase 2a Study on Allogeneic Osteoblastic Cells Implantation in Lumbar Spinal Fusion
Start: Oct 31, 2014
Completion: Jan 25, 2021
NCT03454932
Research Study on the Immunosuppressive Effects of a Cell Therapy Product on PBMC Isolated From Blood of Patients With Inflammatory Rheumatic Diseases
Phase: N/A
Start: May 31, 2015
Completion: Jun 4, 2017
NCT02740231
A Study on Visco-antalgic Intra-articular Administration in Symptomatic Knee Osteoarthritis
Start: Feb 29, 2016
Completion: Apr 27, 2018
NCT03286270
A mRUS Validation Study for Nail-treated Fractures of Long Bones and a TUS Exploratory Study for Nail and Plate-treated Fractures of Long Bones
Start: Sep 1, 2017
NCT04333160
Phase III Study on the Safety and Efficacy of a Single Intra-articular Administration of JTA-004 in Symptomatic Knee Osteoarthritis
Start: Mar 10, 2020
Completion: Dec 9, 2021
NCT04432389
Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB®) Single Implantation in Tibial Fracture
Start: Jan 8, 2021
Completion: Mar 31, 2024